Science Magazine Examines Recent HIV Vaccine Clinical Trial Results

Science magazine reviews the disappointing results of two recent HIV vaccine clinical trials, which “sugges[t] that a successful vaccine, the most effective way to slow if not end the epidemic, lies far in the future.” The news service focuses on the experimental vaccines’ use of adenovirus vectors, which “are widely used in experimental vaccines and gene therapy studies” and show some evidence of increasing the risk of HIV infection. “Other than a large-scale trial of a new and improved version of RV144 set to start in South Africa in 2015, all HIV trials currently in the works are at very early stages,” Science notes (Cohen, 5/10).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.